Breaking News

New unicorn Somatus hauls in $325M+

Not rendering correctly? View this email as a web page here.

Kodiak Sciences' trial failure clouds eye drug's prospects for challenging Eylea

By Frank Vinluan Wednesday, February 23, 2022 7:37 PM

A Kodiak Sciences drug failed to beat a Regeneron Pharmaceuticals product in a key test in the wet form of age-related macular degeneration. The biotech says the failure is due to a subset of undertreated patients, but the results raise the stakes for the drug, its lead product candidate, in other eye diseases.

Read more »

Communication breakdown: Healthcare delivery is still hindered by preventable mistakes

By Subha Airan-Javia, MD Wednesday, February 23, 2022 6:20 PM

Even with EHRs, notes are still written down on paper and some critical communication never happens between clinicians. To reduce medical errors, we need to keep improving our systems for collaboration.

Read more »

Progress report: Vast majority of hospitals still aren't following the price transparency rule

By Michael Schroeder Wednesday, February 23, 2022 5:16 PM

In its second report evaluating whether hospitals are with complying with the price transparency rule that went into effect Jan. 1, 2021, PatientRightsAdvocate.org found compliance to be still very low with none of the hospitals at the nation's largest hospital system posting prices online.

Read more »

Omada Health raises $192M in Series E funding and Verily's Onduo snags a payer partner

By Arundhati Parmar Wednesday, February 23, 2022 4:07 PM

Omada got funds from two new investors – Fidelity Management & Research Company and aMoon as well as existing ones. Verily's Onduo is bringing its virtual diabetes management platform to an integrated care delivery and health plan that has 6 million members in Pennsylvania, West Virginia, Delaware, and New York.

Read more »

Sanofi, GSK Covid-19 vax is now ready for regulators; its future may be as a booster

By Frank Vinluan Wednesday, February 23, 2022 12:53 PM

Sanofi and GlaxoSmithKline weathered clinical trial delays for their Covid-19 vaccine, but the partners now have data to support filings seeking regulatory authorizations. Key features of the vaccine may be able to persuade the vaccine hesitant; it may also be well-suited for use as a booster.

Read more »

   

No comments